Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

CMS Releases Provisional Design of a New Oncology Payment Model

(COA) Aug 13, 2014 - CMS sent the following email to COA President Dr. Bruce Gould, Immediate Past President Dr. Mark Thompson, and other stakeholders who participated in providing input on oncology payment reform.

Commentary: So as we look into the crystal ball I think we are beginning to see the shape of the future. This presentation...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Many Women at High Risk For Ovarian Cancer Don’t Know It

(Fred Hutchinson News Service) Aug 21, 2014 - Seventy-five percent of women at high risk for BRCA mutations have no idea they may have increased chance of ovarian cancer, Hutch study shows.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



CMS Releases Provisional Design of a New Oncology Payment Model (COA)

So as we look into the crystal ball I think we are beginning to see the shape of the future. This presentation...posted by: Thomas Marsland, MD

MD Anderson, Foundation Medicine, Team Up to Improve Targeted Therapies in Metastatic Disease (MD Anderson)

One would hope that this is a major step towards showing clinical utility of genomic profiling in the metastatic...posted by: Winston Wong, PharmD

Another Gene Mutation Increases Breast Cancer Risk (Medscape Medical News)

The research in this area is growing, and exciting. The issue that I see today is that from a payer standpoint,...posted by: Winston Wong, PharmD

The Cost of Treating Cancer Skyrockets When Doctors Merge With Hospitals (FoxNews.com)

This has been a point of contention for many years. Highmark was just the first to take a stand. The problems...posted by: Winston Wong, PharmD

Express Scripts Drops Amgen Anemia Drugs from Formulary (Reuters)

I hate to put a damper on headlines but this is total rational. Epogen is indicated only for dialysis, and Procrit...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Sunesis Pharmaceuticals, Inc. has 2 jobs posted.


Novocure has posted 4 jobs.


View OBR Job Board>>


IMS_White_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
PARD +61.86%
AGIO +8.20%
PVCT +7.70%
CBMG -9.43%
IMNP -5.31%
CRIS -3.94%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: September 2014
Company: Threshold Pharmaceuticals / Merck KGaA
Product: TH-302

Date: September 18, 2014
Company: Astellas Pharma / Medivation
Product: Xtandi® (enzalutamide) capsules

Date: Q3 2014
Company: ERYTECH Pharma
Product: ERY-ASP/GRASPA®

See All OBR Radar items»